SCM
APGE

Soleus Capital Management’s Apogee Therapeutics APGE Stock Holding History

Soleus Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,000
Closed -$598K – 96
2025
Q1 		$598K Sell
16,000
-54,000
-77% -$2.09M 0.04% 73
2024
Q4 		$3.17M Buy
+70,000
New +$3.57M 0.2% 62
2024
Q2 		– Sell
-20,000
Closed -$1.33M – 94
2024
Q1 		$1.33M Sell
20,000
-15,000
-43% -$655K 0.1% 79
2023
Q4 		$978K Hold
35,000
– – 0.11% 62
2023
Q3 		$746K Buy
+35,000
New +$771K 0.07% 83

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Soleus Capital Management's APGE Position: Q2 2025 in Review

Soleus Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2025, closing a stake of 16,000 shares — an estimated $598K sold.

Soleus Capital Management first reported a position in APGE in Q3 2023 and held it in 5 quarters. The position peaked at $3.17M in Q4 2024. 182 funds tracked by Wall St. Rank hold APGE as of Q2 2025.

  • Soleus Capital Management reported no remaining Apogee Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Soleus Capital Management sold 16,000 Apogee Therapeutics shares in Q2 2025, an estimated $598K.
  • Soleus Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and held it in 5 quarters.
  • Soleus Capital Management's Apogee Therapeutics position peaked at $3.17M in Q4 2024.
  • 182 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2025.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.